TY - JOUR
T1 - Advances with pharmacotherapy for the treatment of interstitial lung disease
AU - Comes, Alessia
AU - Sgalla, Giacomo
AU - Perrotta, Alessandro
AU - Richeldi, Luca
PY - 2022
Y1 - 2022
N2 - Introduction: In recent decades, the primary focus of pharmaceutical research in interstitial lung diseases (ILD) has been on idiopathic pulmonary fibrosis (IPF). Recently, pharmaceutical development has also focused on other forms of ILDs, including connective tissue diseases associated ILD, fibrotic hypersensitivity pneumonitis, and sarcoidosis. Areas Covered: The authors summarize the advances in pharmacotherapy for the treatment of ILD. Specifically, the authors review the most recent studies and discuss the most recent research findings and future prospects. Expert opinion: Data collected over the past years have confirmed the efficacy of antifibrotic drugs on slowing disease progression in IPF. The usual strategy for CTD-ILD management is represented by the combined use of corticosteroids and immunosuppressive agents. There is an urgent need for new target therapies. The concept of progressive fibrosing ILD has emerged in the ILD community in recent years, which has led to grouping several diseases with a common disease behavior to find an effective treatment. At present, selecting the best therapy in ILDs should be reasonably performed on a case-by-case basis through a multidisciplinary team discussion in tertiary ILD centers, taking into consideration patients’ symptoms, lung functional trends, and radiological changes.
AB - Introduction: In recent decades, the primary focus of pharmaceutical research in interstitial lung diseases (ILD) has been on idiopathic pulmonary fibrosis (IPF). Recently, pharmaceutical development has also focused on other forms of ILDs, including connective tissue diseases associated ILD, fibrotic hypersensitivity pneumonitis, and sarcoidosis. Areas Covered: The authors summarize the advances in pharmacotherapy for the treatment of ILD. Specifically, the authors review the most recent studies and discuss the most recent research findings and future prospects. Expert opinion: Data collected over the past years have confirmed the efficacy of antifibrotic drugs on slowing disease progression in IPF. The usual strategy for CTD-ILD management is represented by the combined use of corticosteroids and immunosuppressive agents. There is an urgent need for new target therapies. The concept of progressive fibrosing ILD has emerged in the ILD community in recent years, which has led to grouping several diseases with a common disease behavior to find an effective treatment. At present, selecting the best therapy in ILDs should be reasonably performed on a case-by-case basis through a multidisciplinary team discussion in tertiary ILD centers, taking into consideration patients’ symptoms, lung functional trends, and radiological changes.
KW - Disease Progression
KW - Fibrosis
KW - Humans
KW - Idiopathic Pulmonary Fibrosis
KW - Interstitial lung disease
KW - Lung
KW - Lung Diseases, Interstitial
KW - Sarcoidosis
KW - connective tissue disease associated ILD
KW - fibrotic hypersensitivity pneumonitis
KW - idiopathic pulmonary fibrosis
KW - nintedanib
KW - pirfenidone
KW - progressive fibrosing ILD
KW - sarcoidosis
KW - Disease Progression
KW - Fibrosis
KW - Humans
KW - Idiopathic Pulmonary Fibrosis
KW - Interstitial lung disease
KW - Lung
KW - Lung Diseases, Interstitial
KW - Sarcoidosis
KW - connective tissue disease associated ILD
KW - fibrotic hypersensitivity pneumonitis
KW - idiopathic pulmonary fibrosis
KW - nintedanib
KW - pirfenidone
KW - progressive fibrosing ILD
KW - sarcoidosis
UR - http://hdl.handle.net/10807/203427
U2 - 10.1080/14656566.2021.2016697
DO - 10.1080/14656566.2021.2016697
M3 - Article
SN - 1465-6566
VL - 23
SP - 483
EP - 495
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
ER -